Amneal Pharmaceuticals, Inc. (AMRX) › Operating IncomeAmneal Pharmaceuticals, Inc. (AMRX) — Operating IncomeAnnual figures by period end, from SEC filings.2016-12-31: $284.88M2017-12-31: $245.10M2018-12-31: -$19.67M2019-12-31: -$248.68M2020-12-31: $91.16M2021-12-31: $152.72M2022-12-31: -$94.93M2023-12-31: $204.37M2024-12-31: $249.33M2025-12-31: $394.10M$394.10M2016-12-31Operating Income (USD)2025-12-31Period endedOperating IncomeChange YoYSource filing2025-12-31$394.10M+58.1%2026-02-27From 2025-01-012024-12-31$249.33M+22.0%2026-02-27From 2024-01-012023-12-31$204.37M—2026-02-27From 2023-01-012022-12-31-$94.93M-162.2%2025-02-28From 2022-01-012021-12-31$152.72M+67.5%2024-03-14From 2021-01-012020-12-31$91.16M—2023-03-03From 2020-01-012019-12-31-$248.68M—2022-03-01From 2019-01-012018-12-31-$19.67M-108.0%2021-03-01From 2018-01-012017-12-31$245.10M-14.0%2020-03-02From 2017-01-012016-12-31$284.88M—2019-03-01From 2016-01-01Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)